Article Text

PDF
The sudden withdrawal of triazolam – reasons and consequences

Abstract

On 2 October all products containing the benzodiazepine triazolam (Halcion and generic alternatives) were withdrawn from the market in Britain.1,2 Section 118 of the Medicines Act bars the Committee on Safety of Medicines (CSM) from explaining in detail why it advised ministers to suspend the drug's licence. We discuss the background to the decision and its clinical consequences.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.